Section Arrow
RGNX.NASDAQ
- REGENXBIO
Quotes are at least 15-min delayed:2026/04/15 09:36 EDT
Regular Hours
Last
 9.445
+0.145 (+1.56%)
Day High 
9.45 
Prev. Close
9.3 
1-M High
9.42 
Volume 
12.68K 
Bid
9.42
Ask
9.47
Day Low
9.29 
Open
9.29 
1-M Low
7.58 
Market Cap 
480.00M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.79 
20-SMA 8.48 
50-SMA 8.84 
52-W High 16.19 
52-W Low 5.85 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.76/-2.44
Enterprise Value
545.22M
Balance Sheet
Book Value Per Share
1.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
170.44M
Operating Revenue Per Share
1.88
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.9136+0.5988+190.22%-- 
LIMNLiminatus Pharma Inc0.193+0.0132+7.34%-- 
ALLOAllogene Therapeutics1.89-0.39-17.11%-- 
LNAILunai Bioworks Inc.0.3174-0.0214-6.32%-- 
RVMDRevolution Medicines149.89+2.88+1.96%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeuticproteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.